Pretransplant Bioconjugation of Renal Endothelial Surfaces for TAK-242 Drug Delivery

Abstract Transplantation provides a unique opportunity wherein donor tissue is isolated ex vivo and available for tissue-specific manipulation prior to implantation. We previously demonstrated improved graft performance with covalently modified drug-eluting islets. In this work we provide preliminary studies extending the concept of covalent tissue modification for drug delivery to renal transplantation and demonstrate that the perfusion of reactive N-hydroxysuccinimide (NHS) esters through the renal artery affords the covalent modification of kidney vascular surfaces. The fluorescent labeling of vascular surface proteins has minimal impact on clinical markers of kidney function and host immune responses in murine isografts and allografts over 5 weeks. Additionally, histological analysis of modified graft tissue resected on day 35 reveals no gross abnormalities, with some covalent label still detectable. In a preliminary study, bioconjugation of renal vasculature with a slow-release prodrug of TAK-242 (a potent inhibitor of toll-like receptor 4) modulated the expression of inflammatory cytokines and reduced T-cell infiltration into graft tissue 48 h posttransplant.

Authors

Institutions

Publication Details

Journal
ACS Omega
Published
2026-10-30
DOI
https://doi.org/10.1021/acsomega.6c07422
Primary Topic
Renal Transplantation Outcomes and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pretransplant Bioconjugation of Renal Endothelial Surfaces for TAK-242 Drug Delivery

Anna Valujskikh, Rahul N. Gaykar, William M. Baldwin, Michael Nicosia et al.
ACS Omega
Renal Transplantation Outcomes and Treatments
article

Pretransplant Bioconjugation of Renal Endothelial Surfaces for TAK-242 Drug Delivery

Anna Valujskikh, Rahul N. Gaykar, William M. Baldwin, Michael Nicosia, Johann W. Karunananthan, Ran Fan, Robert R. Kane, Victoria Gorbacheva, José Ignacio Valenzuela, Isaiah A. Rivera
article en

Abstract

Abstract Transplantation provides a unique opportunity wherein donor tissue is isolated ex vivo and available for tissue-specific manipulation prior to implantation. We previously demonstrated improved graft performance with covalently modified drug-eluting islets. In this work we provide preliminary studies extending the concept of covalent tissue modification for drug delivery to renal transplantation and demonstrate that the perfusion of reactive N-hydroxysuccinimide (NHS) esters through the renal artery affords the covalent modification of kidney vascular surfaces. The fluorescent labeling of vascular surface proteins has minimal impact on clinical markers of kidney function and host immune responses in murine isografts and allografts over 5 weeks. Additionally, histological analysis of modified graft tissue resected on day 35 reveals no gross abnormalities, with some covalent label still detectable. In a preliminary study, bioconjugation of renal vasculature with a slow-release prodrug of TAK-242 (a potent inhibitor of toll-like receptor 4) modulated the expression of inflammatory cytokines and reduced T-cell infiltration into graft tissue 48 h posttransplant.

ACS Omega
Cleveland Clinic (US), Baylor University (US)
National Institutes of Health, National Institute of Allergy and Infectious Diseases, Congressionally Directed Medical Research Programs, JDRF
Good health and well-being
Openalex Percentile: Top 9%
Renal Transplantation Outcomes and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon